Impact Factor
3.42
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.61
942 total citations
h5-index
29
h5 depth signal
Cited share
70.3%
270 of 384
Total citations
942
Citation footprint
Metric signal
2.96
External metric anchor
Self-citation
7.9%
74 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Japan
1,782
China
234
United States
123
South Korea
99
United Kingdom
37
Citing Fields of Research
Oncology
778
Lung Cancer
325
Liver & Colon Cancer
234
Urology
230
Breast Cancer
208
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
7,128
Articles tracked across the journal lifetime
Indexed publication set
384
270 cited publications
Last 12 months
241
20.1 publications/month
Open access share
23.2%
56 OA publications in the last year
Leading citing country
Japan
1,782 citing publications
Leading citing field
Oncology
778 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v13n1, 1983-
v13n1, 1983-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Lung Cancer
Prostate Cancer
Urology
Musculoskeletal & Nerve Cancer
Liver & Colon Cancer
Issuing & Sponsoring Bodies
Contributor
Foundation of Clinical Oncology
Contributor
Gan Kenkyu Shinkokai
Broad Categories
Neoplasms
Lung Cancer
Digestive Disorders
Urology
Musculoskeletal & Nerve Cancer
Prostate Cancer
Liver & Colon Cancer
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1093/jjco/hyag176
Open DOI
Efficacy and safety of immunotherapy plus chemotherapy in elderly patients with advanced gastric cancer: a retrospective study
Background: This study investigated the efficacy and safety of immunotherapy plus chemotherapy in elderly patients with human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer (AGC). Methods: This single-center r...
02
DOI 10.1093/jjco/hyag175
Open DOI
Integrated host vulnerability assessment using prognostic nutritional index and psoas muscle index for predicting chemotherapy-related toxicity in ovarian cancer: a multicenter JGOG9005S cohort analysis
Objective: To evaluate associations of prechemotherapy prognostic nutritional index (PNI) and computed tomography (CT)-derived muscle measures with severe chemotherapy-related toxicity in ovarian cancer and explore their combined assessm...
03
DOI 10.1093/jjco/hyag174
Open DOI
Primary feasibility analysis of neoadjuvant chemotherapy with bevacizumab for resectable stage II/IIIA non-squamous non-small cell lung cancer: the NAVAL phase II study
Objectives: Bevacizumab (Bev) improves the response and survival rates in patients with advanced non-small cell lung cancer (NSCLC). This phase II trial aimed to assess the feasibility of adding Bev to preoperative chemotherapy in resect...
04
DOI 10.1093/jjco/hyag173
Open DOI
Prognostic impact of lenvatinib dose intensity in previously untreated patients with advanced renal cell carcinoma receiving lenvatinib plus pembrolizumab
Background: Lenvatinib plus pembrolizumab is the standard of care as first-line systemic therapy for advanced renal cell carcinoma (RCC). However, the prognostic impact of the relative dose intensity (RDI) of lenvatinib remains unclear. ...
05
06
DOI 10.1093/jjco/hyag172
Open DOI
Age- and sex-specific prevalence of deficient mismatch repair protein expression in gastric, colorectal, and endometrial cancers: a center-based study of older Japanese patients
Background: Recent advancements in immunotherapy have revolutionized microsatellite instability-high (MSI-H) tumor management. Given the higher prevalence of MSI-H/deficient mismatch repair (dMMR) in older and female patients, characteri...
07
DOI 10.1093/jjco/hyag171
Open DOI
HALP is a novel marker for predicting overall survival in patients with malignant soft tissue sarcoma: a retrospective study
Background: Malignant soft tissue sarcomas (STSs) are rare, aggressive tumors with diverse subtypes and variable prognoses. Current prognostic markers, such as tumor size and grade, do not sufficiently predict postoperative outcomes. The...
08
DOI 10.1093/jjco/hyag170
Open DOI
External validation of a three-variable Ewing sarcoma prognostic score and incremental value of the Glasgow prognostic score in adults: a multicenter cohort study
Objective: To externally validate a three-variable Ewing sarcoma score and assess the incremental prognostic value of the Glasgow prognostic score (GPS) in adults. Methods: This retrospective cohort included 133 adults treated at 10 Turk...
09
DOI 10.1093/jjco/hyag158
Open DOI
Interpreting TP53 pathogenic variants in germline testing and cancer genomics: pathogenicity, origin, and clinical actionability
Next-generation sequencing has increased the sensitivity of pathogenic variant (PV) detection and enabled the quantitative assessment of variant allele fractions (VAFs) in clinical cancer genetics. However, these advances have exposed th...
10
DOI 10.1093/jjco/hyag169
Open DOI
Molecular targeted therapies for pediatric low-grade gliomas: current perspectives and future directions
Pediatric low-grade gliomas (pLGGs) are a heterogeneous group of tumors characterized by frequent activation of the mitogen-activated protein kinase (MAPK) signaling pathway, often driven by a single oncogenic alteration. Recent advances...
Bibliographical & Catalog Notes
Supported by funds from the Society for Promotion of Cancer Research.
Also issued online.